Skip to main content

REVIEW article

Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1438030

Revolutionizing Adjuvant Development: Harnessing AI for Next-Generation Cancer Vaccines

Provisionally accepted
Wanying Zhang Wanying Zhang 1,2Xiao-Li Zheng Xiao-Li Zheng 1,2*Paolo S. Coghi Paolo S. Coghi 1,2Jun-Hui Chen Jun-Hui Chen 3*Bing-Jun Dong Bing-Jun Dong 4*Xing-xing Fan Xing-xing Fan 1,2*
  • 1 Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China
  • 2 Macau Institute for Applied Research in Medicine and Health, Macau, Macao, SAR China
  • 3 Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China
  • 4 Zhuhai City Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong Province, China

The final, formatted version of the article will be published soon.

    With the COVID-19 pandemic, the importance of vaccines has been widely recognized and has led to increased research and development efforts. Vaccines also play a crucial role in cancer treatment by activating the immune system to target and destroy cancer cells. However, enhancing the efficacy of cancer vaccines remains a challenge. Adjuvants, which enhance the immune response to antigens and improve vaccine effectiveness, have faced limitations in recent years, resulting in few novel adjuvants being identified. The advancement of artificial intelligence (AI) technology in drug development has provided a foundation for adjuvant screening and application, leading to a diversification of adjuvants. This article reviews the significant role of tumor vaccines in basic research and clinical treatment and explores the use of AI technology to screen novel adjuvants from databases. The findings of this review offer valuable insights for the development of new adjuvants for next-generation vaccines.

    Keywords: ai drug discovery, vaccine adjuvant, Cancer, immune agonist, Small molecular

    Received: 24 May 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Zhang, Zheng, Coghi, Chen, Dong and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiao-Li Zheng, Macau Institute for Applied Research in Medicine and Health, Macau, Macao, SAR China
    Jun-Hui Chen, Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China
    Bing-Jun Dong, Zhuhai City Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong Province, China
    Xing-xing Fan, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.